SCHEMBL3143209

SCHEMBL3143209

O=[N+]([O-])c1ccnc(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 6/20 0.42
TDP1 Q9NUW8 4/20 0.42
CYP3A4 P08684 2/20 0.42
NAMPT P43490 1/20 0.42
XDH P47989 1/20 0.42
HSD17B10 Q99714 1/20 0.41
TXNRD1 Q16881 1/20 0.40
TXNRD3 Q86VQ6 1/20 0.40
TXNRD2 Q9NNW7 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PDE4D Q08499 1/20 0.40
PTPRC P08575 1/20 0.39
S100A4 P26447 1/20 0.39
ACHE P22303 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29979690 1.00 TSHR (0.46) TSHRLMNAALDH1A1TDP1CYP3A4
Ammonia Solution, Strong SCHEMBL28271262 0.98 TSHR (0.45) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL23829919 0.79 ALDH1A1 (0.47) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL826630 0.78 TSHR (0.50) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL30389430 0.78 ALDH1A1 (0.46) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL28720537 0.77 TSHR (0.48) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL3311690 0.75 ALDH1A1 (0.48) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL1917858 0.75 TSHR (0.46) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL2144876 0.75 TSHR (0.50) TSHRLMNAALDH1A1TDP1CYP3A4
SCHEMBL7942312 0.75 GAA (0.50) TSHRLMNAALDH1A1TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106588915-B The synthetic method of Alzheimer's disease Protein tau diagnosis and treatment one targeted drug precursor 浙江大学 2018-12-04 CN claimed
CN-106588915-A Synthesis method of diagnosis and treatment integrated target prodrug for AD (Alzheimer's disease) tau protein 浙江大学 2017-04-26 CN claimed
CN-101221169-A Homogeneous phase time discrimination fluorescence immunity analysis chelating agent and its preparing method CHANGCHUN APPLIED CHEMISTRY (CN) 2008-07-16 CN claimed
CN-115650982-B Compounds for imaging TAU protein aggregates AC免疫有限公司 2026-05-19 CN disclosed
CN-121537340-A 4,4' - (Perfluoropropane-2, 2-diyl) bis (2- ((4-aminopyridine-2-yl) amino) phenol), and preparation method and application thereof 山东阳谷华泰化工股份有限公司 2026-02-17 CN disclosed
EP-4665331-A1 ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2025-12-24 EP disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
WO-2024173219-A1 ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-08-22 WO disclosed
US-12053459-B2 CDK2 inhibitors and methods of using the same CEDILLA THERAPEUTICS, INC. (MA) 2024-08-06 US disclosed
US-20240199603-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-06-20 US disclosed
CN-1551876-A 6-aryl-4-aminopicolinates and their use as herbicides �ݶ�ũ�����޹�˾ 2004-12-01 CN disclosed
CN-1148356-C Benzosulfone derivatives - 2004-05-05 CN disclosed
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed
CN-1231287-A Benzosulfone derivatives HOFFMANN LA ROCHE (CH) 1999-10-13 CN disclosed
EP-0711601-A2 Catalyst for multistage etherification with high conversion of T-butanol TEXACO DEVELOPMENT CORPORATION (US) 1996-05-15 EP disclosed
US-5196422-A Antiinflammatory agents, antiallergens ICI PHARMA (FR) 1993-03-23 US disclosed
US-5089513-A Antiinflammatory agents; antiallergens; asthma; side effect reduction ICI PHARMA (FR) 1992-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199603-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 TSHR 4353/4885LMNA 3355/4885ALDH1A1 4740/4885
US-12053459-B2 CDK2 inhibitors and methods of using the same CDK2, CDK20, CDK2AP2 TSHR 3996/4885LMNA 1270/4885ALDH1A1 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.